Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18922705 | 0.90 | HTR3A (0.53) | HTR3AALDH1A1HTR7LMNANR4A2 | |
| SCHEMBL17170607 | 0.86 | ALDH1A1 (0.53) | HTR3AALDH1A1TSHRLMNAHTT | |
| SCHEMBL15444633 | 0.86 | HTR3A (0.56) | HTR3AALDH1A1HTR7LMNANR4A2 | |
| SCHEMBL17170671 | 0.86 | HTR3A (0.57) | HTR3AALDH1A1TSHRLMNAHTT | |
| SCHEMBL15441066 | 0.85 | HTR3A (0.55) | HTR3AALDH1A1TSHRLMNA | |
| SCHEMBL17170663 | 0.84 | HTR3A (0.56) | HTR3AALDH1A1TSHRLMNAHTT | |
| SCHEMBL6044056 | 0.83 | HTR3A (0.53) | HTR3ATSHRHTR7NR4A2POLB | |
| SCHEMBL15420930 | 0.81 | NR4A2 (0.64) | HTR3AALDH1A1TSHRLMNANR4A2 | |
| SCHEMBL20080348 | 0.81 | KMT2A (0.52) | HTR3AALDH1A1TSHRHTR7LMNA | |
| SCHEMBL15440909 | 0.81 | HTR3A (0.57) | HTR3AALDH1A1TSHRLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407443-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3312169-A1 | 5-HT3 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9670229-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9670229-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160251373-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-9346829-B2 | 5-HT3 receptor antagonists | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | US | disclosed |
| US-9012447-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-21 | — | — | US | disclosed |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407443-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | HTR3A 1/4885ALDH1A1 1329/4885TSHR 336/4885 |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885ALDH1A1 1329/4885TSHR 336/4885 |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR3E | HTR3A 1/4885ALDH1A1 1138/4885TSHR 246/4885 |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885ALDH1A1 1329/4885TSHR 336/4885 |
| US-20160251373-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885ALDH1A1 1329/4885TSHR 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.